Research paperSuppression of NF-κB and NF-κB regulated oxidative stress and neuroinflammation by BAY 11-7082 (cas 19542-67-7) (IκB phosphorylation inhibitor) in experimental diabetic neuropathy
-
Add time:08/28/2019 Source:sciencedirect.com
Inflammation is an emerging patho-mechanism of diabetes and its complications. NF-κB pathway is one of the central machinery initiating and propagating inflammatory responses. The present study envisaged the involvement of NF-κB inflammatory cascade in the pathophysiology of diabetic neuropathy using BAY 11-7082 (cas 19542-67-7), an IκB phosphorylation inhibitor. Streptozotocin was used to induce diabetes in Sprauge Dawley rats. BAY 11-7082 (1 & 3 mg/kg) was administered to diabetic rats for 14 days starting from the end of six weeks post diabetic induction. Diabetic rats developed deficits in nerve functions and altered nociceptive parameters and also showed elevated expression of NF-κB (p65), IκB and p-IκB along with increased levels of IL-6 & TNF-α and inducible enzymes (COX-2 and iNOS). Furthermore, there was an increase in oxidative stress and decrease in Nrf2/HO-1 expression. We observed that BAY 11-7082 alleviated abnormal sensory responses and deficits in nerve functions. BAY 11-7082 also ameliorated the increase in expression of NF-κB, IκB and p-IκB. BAY 11-7082 curbed down the levels of IL-6, TNF-α, COX-2 and iNOS in the sciatic nerve. Lowering of lipid peroxidation and improvement in GSH levels was also seen along with increased expression of Nrf2/HO-1. Thus it can be concluded that NF-κB expression and downstream expression of proinflammatory mediators are prominent features of nerve damage leading to inflammation and oxidative stress and BAY 11-7082 was able to ameliorate experimental diabetic neuropathy by modulating neuroinflammation and improving antioxidant defence.
We also recommend Trading Suppliers and Manufacturers of BAY 11-7082 (cas 19542-67-7). Pls Click Website Link as below: cas 19542-67-7 suppliers
Prev:Inhibition of NF-κB activity by BAY 11-7082 (cas 19542-67-7) increases apoptosis in multidrug resistant leukemic T-cell lines
Next:Shortcomings of protein removal prior to high performance liquid chromatographic analysis—A case study using method development for BAY 11-7082 (cas 19542-67-7)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Shortcomings of protein removal prior to high performance liquid chromatographic analysis—A case study using method development for BAY 11-7082 (cas 19542-67-7)08/29/2019
- Inhibition of NF-κB activity by BAY 11-7082 (cas 19542-67-7) increases apoptosis in multidrug resistant leukemic T-cell lines08/27/2019
- The inhibitor of IkappaBalpha phosphorylation BAY 11-7082 (cas 19542-67-7) prevents NMDA neurotoxicity in mouse hippocampal slices08/26/2019
- BAY 11-7082 (cas 19542-67-7) induces cell death through NF-κB-independent mechanisms in the Ewing’s sarcoma family of tumours08/25/2019
- Molecular and Cellular PharmacologyA noble function of BAY 11-7082 (cas 19542-67-7): Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations08/24/2019
- BAY 11-7082 (cas 19542-67-7) ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway08/23/2019
- In Vivo Short-Term Topical Application of BAY 11-7082 (cas 19542-67-7) Prevents the Acidic Bile–Induced mRNA and miRNA Oncogenic Phenotypes in Exposed Murine Hypopharyngeal Mucosa1208/22/2019
-
Health and Chemical more >
-
Related Products


